MedTrace Logo

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

NCT05661084 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-01-12

No results posted yet for this study

Summary

This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.

Conditions

  • Dementia
  • Memory Loss
  • Alzheimer Disease
  • Executive Dysfunction
  • Mobility Limitation

Interventions

DEVICE

Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)

Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.

DEVICE

Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)

A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.

DEVICE

Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)

Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.

DEVICE

Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)

Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.

Sponsors & Collaborators

  • Hebrew SeniorLife

    lead OTHER

  • BrightFocus Foundation

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

Principal Investigators

  • Alvaro Pascual-Leone, MD; PhD · Hebrew SeniorLife

  • Brad Manor, PhD · Hebrew SeniorLife

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-24
Primary Completion
2026-12-31
Completion
2027-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05661084 on ClinicalTrials.gov